Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPHT message board posts where the ticker symbol OPHT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPHT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-18-008981 (34 Act)  Size: 52 KB
2018-02-14 005-87636
18613350
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000919574-18-001637 (34 Act)  Size: 114 KB
2018-02-14 005-87636
18608731
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001037389-18-000047 (34 Act)  Size: 13 KB
2018-02-14 005-87636
18606595
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000935836-18-000118 (34 Act)  Size: 58 KB
2018-02-13 005-87636
18604665
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-004528 (34 Act)  Size: 45 KB
2018-02-12 005-87636
18595025
8-K  Documents Current report, item 5.02
Acc-no: 0001410939-18-000006 (34 Act)  Size: 27 KB
2018-01-19 001-36080
18535482
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-002660 Size: 5 KB
2018-01-17
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001104659-18-002659 Size: 12 KB
2018-01-17
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001410939-18-000004 (34 Act)  Size: 3 MB
2018-01-10 001-36080
18520365
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-001015 Size: 9 KB
2018-01-05
More OPHT SEC Filings


Related news from
Wed, 21 Feb 2018
12:30:00 +0000
Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018
Ophthotech Corporation today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
Fri, 09 Feb 2018
13:25:00 +0000
Market Trends Toward New Normal in Innospec, Southern Copper, Cornerstone OnDemand, Eagle, Northwest Natural Gas, and Ophthotech — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Innospec ...
Wed, 24 Jan 2018
12:33:01 +0000
Nektar’s Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb
A Look at Nektar Therapeutics' Revenue Drivers in 2018
Wed, 17 Jan 2018
14:56:02 +0000
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.
Tue, 16 Jan 2018
12:30:00 +0000
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
Ophthotech Corporation announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® , complement C5 inhibitor, in patients with autosomal recessive Stargardt disease .
Tue, 16 Jan 2018
12:15:00 +0000
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors
Ophthotech Corporation announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
Tue, 02 Jan 2018
12:30:00 +0000
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference
Ophthotech Corporation announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Wed, 13 Dec 2017
19:12:00 +0000
Robbins Arroyo LLP Is Investigating the Officers and Directors of Ophthotech Corporation (OPHT) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ophthotech Corporation breached their fiduciary duties to shareholders.
Tue, 12 Dec 2017
22:49:10 +0000
Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Mon, 11 Dec 2017
10:02:10 +0000
Ophthotech (OPHT) Up 7.1% Since Earnings Report: Can It Continue?
Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mon, 20 Nov 2017
18:01:25 +0000
ETFs with exposure to Ophthotech Corp. : November 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ophthotech Corp. Here are 5 ETFs with the largest exposure to OPHT-US. Comparing the performance and risk of Ophthotech Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Tue, 14 Nov 2017
13:43:01 +0000
Ophthotech (OPHT) Jumps: Stock Rises 11.9%
Ophthotech Corporation (OPHT) saw its shares rise nearly 12% on the day.
Tue, 14 Nov 2017
01:31:01 +0000
Edited Transcript of OPHT earnings conference call or presentation 8-Nov-17 1:00pm GMT
Q3 2017 Ophthotech Corp Earnings Call
Mon, 13 Nov 2017
19:20:07 +0000
Vertex Gets CHMP Recommendation for Orkambi Label Expansion
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.
Thu, 09 Nov 2017
14:48:38 +0000
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
Categories: Yahoo FinanceGet free summary analysis Ophthotech Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Ophthotech Corp. – Alimera Sciences, Inc., Insmed Incorporated and Nektar Therapeutics (ALIM-US, INSM-US and NKTR-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 206.65 ... Read more <b>(Read more...)</b>
Thu, 09 Nov 2017
14:16:02 +0000
Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus
Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.
Thu, 09 Nov 2017
13:10:00 +0000
Today’s Research Reports on Stocks to Watch: Ophthotech Corporation and HTG Molecular Diagnostics
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Ophthotech and HTG Molecular Diagnostics both saw green on Wednesday after announcing strong third quarter reports. Ophthotech also announced that it is on ...
Wed, 08 Nov 2017
14:30:00 +0000
Ophthotech Soars After Third-Quarter Results -- Biotech Movers
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF has been a blessing to me and my family. Even if you are not a big contributor, the information is there for you to read. It is amazing that the fine members of VF will openly help and provide ideas to enhance each others investing." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards